IDEAYA Biosciences, Inc. presented positive interim data from its ongoing Phase 2 OptimUM-09 trial of darovasertib in the neoadjuvant setting for primary uveal melanoma (UM) on September 8, 2025. The data was showcased at the company's 10-Year Anniversary R&D Day.
The presented clinical evidence demonstrated ocular tumor shrinkage and a reduction in radiation doses administered to critical eye structures. This, in turn, led to improved vision and a reduced risk of developing longer-term blindness post-treatment.
Dr. Arun D. Singh, Director of Ophthalmic Oncology at the Cole Eye Institute, Cleveland Clinic, presented the data and discussed the design and objectives of IDEAYA's recently initiated Phase 3 OptimUM-10 trial. This trial aims to support a potential approval for darovasertib in this indication, addressing a high unmet medical need.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.